{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T10:23:02Z","timestamp":1790504582814,"version":"4.1.0"},"reference-count":116,"publisher":"IMR Press","issue":"2","license":[{"start":{"date-parts":[[2020,6,30]],"date-time":"2020-06-30T00:00:00Z","timestamp":1593475200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Rev. Cardiovasc. Med."],"abstract":"<jats:p>Pulmonary arterial hypertension (PAH) is a progressive and fatal lung disease of multifactorial etiology. Most of the available drugs and FDA-approved therapies for treating pulmonary hypertension attempt to overcome the imbalance between vasoactive and vasodilator mediators, and restore the endothelial cell function. Traditional medications for treating PAH include the prostacyclin analogs and receptor agonists, phosphodiesterase 5 inhibitors, endothelin-receptor antagonists, and cGMP activators. While the current FDA-approved drugs showed improvements in quality of life and hemodynamic parameters, they have shown only very limited beneficial effects on survival and disease progression. None of them offers a cure against PAH, and the median survival rate remains less than three years from diagnosis. Extensive research efforts have led to the emergence of innovative therapeutic approaches in the area of PAH. In this review, we provide an overview of the current FDA-approved therapies in PAH and discuss the associated clinical trials and reported-side effects. As recent studies have led to the emergence of innovative therapeutic approaches in the area of PAH, we also focus on the latest promising therapies in preclinical studies such as stem cell-based therapies, gene transfer, and epigenetic therapies.<\/jats:p>","DOI":"10.31083\/j.rcm.2020.02.597","type":"journal-article","created":{"date-parts":[[2020,7,1]],"date-time":"2020-07-01T07:12:31Z","timestamp":1593587551000},"source":"Crossref","is-referenced-by-count":84,"title":["Current and emerging therapeutic approaches to pulmonary hypertension"],"prefix":"10.31083","volume":"21","author":[{"given":"Malik","family":"Bisserier","sequence":"first","affiliation":[{"name":"Cardiovascular Research Center, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natasha","family":"Pradhan","sequence":"first","affiliation":[{"name":"Cardiovascular Research Center, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lahouaria","family":"Hadri","sequence":"first","affiliation":[{"name":"Cardiovascular Research Center, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"16242","published-online":{"date-parts":[[2020,6,30]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","unstructured":"Aguero, J., Ishikawa, K., Hadri, L., Santos-Gallego, C. G., Fish, K. M., Kohlbrenner, E., Hammoudi, N., Kho, C., Lee, A., Ibanez, B., Garcia-Alvarez, A., Zsebo, K., Maron, B. A., Plataki, M., Fuster, V., Leopold, J. A. and Hajjar, R. J. (2016) Intratracheal gene delivery of SERCA2a ameliorates chronic post-capillary pulmonary hypertension: a large animal model. Journal of the American College of Cardiology 67, 2032-2046.","DOI":"10.1016\/j.jacc.2016.02.04927126531https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/27126531"},{"key":"ref2","doi-asserted-by":"publisher","unstructured":"Alison, M. R., Poulsom, R., Forbes, S. and Wright, N. A. (2002) An introduction to stem cells. The Journal of Pathology 197, 419-423.","DOI":"10.1002\/path.118712115858https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/12115858"},{"key":"ref3","doi-asserted-by":"publisher","unstructured":"Archer, S. L., Marsboom, G., Kim, G. H., Zhang, H. J., Toth, P. T., Svensson, E. C., Dyck, J. R., Gomberg-Maitland, M., Thebaud, B., Husain, A. N., Cipriani, N. and Rehman, J. (2010) Epigenetic attenuation of mitochondrial superoxide dismutase 2 in pulmonary arterial hypertension: a basis for excessive cell proliferation and a new therapeutic target. Circulation 121, 2661-2671.","DOI":"10.1161\/CIRCULATIONAHA.109.91609820529999https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/20529999"},{"key":"ref4","doi-asserted-by":"publisher","unstructured":"Asahara, T., Murohara, T., Sullivan, A., Silver, M., van der Zee, R., Li, T., Witzenbichler, B., Schatteman, G. and Isner, J. M. (1997) Isolation of putative progenitor endothelial cells for angiogenesis. Science 275, 964-967.","DOI":"10.1126\/science.275.5302.9649020076https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/9020076"},{"key":"ref5","doi-asserted-by":"publisher","unstructured":"Atkinson, C., Stewart, S., Upton, P. D., Machado, R., Thomson, J. R., Trembath, R. C. and Morrell, N. W. (2002) Primary pulmonary hypertension is associated with reduced pulmonary vascular expression of type II bone morphogenetic protein receptor. Circulation 105, 1672-1678.","DOI":"10.1161\/01.cir.0000012754.72951.3d11940546https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/11940546"},{"key":"ref6","doi-asserted-by":"publisher","unstructured":"Auricchio, A., O'Connor, E., Weiner, D., Gao, G. P., Hildinger, M., Wang, L., Calcedo, R. and Wilson, J. M. (2002) Noninvasive gene transfer to the lung for systemic delivery of therapeutic proteins. Journal of Clinical Investigation 110, 499-504.","DOI":"10.1172\/JCI1578012189244https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/12189244"},{"key":"ref7","doi-asserted-by":"publisher","unstructured":"Austin, E. D. and Loyd, J. E. (2014) The genetics of pulmonary arterial hypertension. Circulation Research 115, 189-202.","DOI":"10.1161\/CIRCRESAHA.115.303404cb61a242-01fc-4d5c-bd72-9547eac5c42fhttp:\/\/dx.doi.org\/10.1161\/CIRCRESAHA.115.303404"},{"key":"ref8","doi-asserted-by":"publisher","unstructured":"Badesch, D. B., McGoon, M. D., Barst, R. J., Tapson, V. F., Rubin, L. J., Wigley, F. M., Kral, K. M., Raphiou, I. H. and Crater, G. D. (2009) Longterm survival among patients with scleroderma-associated pulmonary arterial hypertension treated with intravenous epoprostenol. Journal of Rheumatology 36, 2244-2249.","DOI":"10.3899\/jrheum.08127719723905https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/19723905"},{"key":"ref9","doi-asserted-by":"publisher","unstructured":"Badesch, D. B., Tapson, V. F., McGoon, M. D., Brundage, B. H., Rubin, L. J., Wigley, F. M., Rich, S., Barst, R. J., Barrett, P. S., Kral, K. M., Jobsis, M. M., Loyd, J. E., Murali, S., Frost, A., Girgis, R., Bourge, R. C., Ralph, D. D., Elliott, C. G., Hill, N. S., Langleben, D., Schilz, R. J., McLaughlin, V. V., Robbins, I. M., Groves, B. M., Shapiro, S. and Medsger, T. A., Jr. (2000) Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease. A randomized, controlled trial. Annals of Internal Medicine 132, 425-434.","DOI":"10.7326\/0003-4819-132-6-200003210-0000210733441https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/10733441"},{"key":"ref10","doi-asserted-by":"publisher","unstructured":"Baliga, R. S., MacAllister, R. J. and Hobbs, A. J. (2011) New perspectives for the treatment of pulmonary hypertension. British Journal of Pharmacology 163, 125-140.","DOI":"10.1111\/j.1476-5381.2010.01164.xf015ad7f-34f2-4501-a7de-834c58371bc0http:\/\/dx.doi.org\/10.1111\/j.1476-5381.2010.01164.x"},{"key":"ref11","doi-asserted-by":"crossref","unstructured":"Barst, R. (2010) How has epoprostenol changed the outcome for patients with pulmonary arterial hypertension? International Journal of Clinical Practice 23-32. 9796552https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/9796552","DOI":"10.1111\/j.1742-1241.2010.02525.x"},{"key":"ref12","doi-asserted-by":"crossref","unstructured":"Barst, R. J., McGoon, M., Torbicki, A., Sitbon, O., Krowka, M. J., Olschewski, H. and Gaine, S. (2004) Diagnosis and differential assessment of pulmonary arterial hypertension. Journal of the American College of Cardiology 43, 40S-47S. 15194177https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/15194177","DOI":"10.1016\/j.jacc.2004.02.032"},{"key":"ref13","doi-asserted-by":"publisher","unstructured":"Barst, R. J., Rubin, L. J., Long, W. A., McGoon, M. D., Rich, S., Badesch, D. B., Groves, B. M., Tapson, V. F., Bourge, R. C., Brundage, B. H., Koerner, S. K., Langleben, D., Keller, C. A., Murali, S., Uretsky, B. F., Clayton, L. M., Jobsis, M. M., Blackburn, S. D., Shortino, D., Crow, J. W. and Primary Pulmonary Hypertension Study, G. (1996) A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. New England Journal of Medicine 334, 296-301.","DOI":"10.1056\/NEJM1996020133405048532025https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/8532025"},{"key":"ref14","doi-asserted-by":"publisher","unstructured":"Bisserier, M., Janostiak, R., Lezoualc\u2019h, F. and Hadri, L. (2020) Targeting epigenetic mechanisms as an emerging therapeutic strategy in pulmonary hypertension disease. Vascular Biology 2, R17-R34.","DOI":"10.1530\/VB-19-0030https:\/\/vb.bioscientifica.com\/view\/journals\/vb\/2\/1\/VB-19-0030.xml"},{"key":"ref15","doi-asserted-by":"crossref","unstructured":"Brouwer, K. M., Hoogenkamp, H. R., Daamen, W. F. and van Kuppevelt, T. H. (2013) Regenerative medicine for the respiratory system: distant future or tomorrow's treatment? American Journal of Respiratory and Critical Care Medicine 187, 468-475. 23220914https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/23220914","DOI":"10.1164\/rccm.201208-1558PP"},{"key":"ref16","doi-asserted-by":"publisher","unstructured":"Buckley, M. S., Staib, R. L., Wicks, L. M. and Feldman, J. P. (2010) Phosphodiesterase-5 inhibitors in management of pulmonary hypertension: safety, tolerability, and efficacy. Drug, Healthcare and Patient Safety 2, 151-161.","DOI":"10.2147\/DHPS.S621521701627https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/21701627"},{"key":"ref17","doi-asserted-by":"publisher","unstructured":"Burchfield, J. S. and Dimmeler, S. (2008) Role of paracrine factors in stem and progenitor cell mediated cardiac repair and tissue fibrosis. Fibrogenesis & Tissue Repair 1, 4.","DOI":"10.1186\/1755-1536-1-419014650https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/19014650"},{"key":"ref18","doi-asserted-by":"publisher","unstructured":"Channick, R. N., Simonneau, G., Sitbon, O., Robbins, I. M., Frost, A., Tapson, V. F., Badesch, D. B., Roux, S., Rainisio, M., Bodin, F. and Rubin, L. J. (2001) Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo-controlled study. Lancet 358, 1119-1123.","DOI":"10.1016\/S0140-6736(01)06250-X11597664https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/11597664"},{"key":"ref19","doi-asserted-by":"crossref","unstructured":"Cheng, X., Wang, Y. and Du, L. (2019) Epigenetic modulation in the initiation and progression of pulmonary hypertension. Hypertension 74, 733-739. 31476913https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/31476913","DOI":"10.1161\/HYPERTENSIONAHA.119.13458"},{"key":"ref20","doi-asserted-by":"crossref","unstructured":"Chin, M., Levy, R. D., Yoshida, E. M. and Byrne, M. F. (2012) Sitaxsentan-induced acute severe hepatitis treated with glucocorticoid therapy. Canadian Respiratory Journal 19, e1-2. 22332138https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/22332138","DOI":"10.1155\/2012\/567024"},{"key":"ref21","doi-asserted-by":"publisher","unstructured":"Cho, Y. K., Eom, G. H., Kee, H. J., Kim, H. S., Choi, W. Y., Nam, K. I., Ma, J. S. and Kook, H. (2010) Sodium valproate, a histone deacetylase inhibitor, but not captopril, prevents right ventricular hypertrophy in rats. Circulation Journal 74, 760-770.","DOI":"10.1253\/circj.cj-09-058020208383https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/20208383"},{"key":"ref22","doi-asserted-by":"publisher","unstructured":"Condon, D. F., Nickel, N. P., Anderson, R., Mirza, S. and de Jesus Perez, V. A. (2019) The 6th world symposium on pulmonary hypertension: what's old is new. F1000Research 8,","DOI":"10.12688\/f1000research.18846.132477495https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/32477495"},{"key":"ref23","doi-asserted-by":"publisher","unstructured":"D'Alonzo, G. E., Barst, R. J., Ayres, S. M., Bergofsky, E. H., Brundage, B. H., Detre, K. M., Fishman, A. P., Goldring, R. M., Groves, B. M., Kernis, J. T. and et al. (1991) Survival in patients with primary pulmonary hypertension. Results from a national prospective registry. Annals of Internal Medicine 115, 343-349.","DOI":"10.7326\/0003-4819-115-5-3431863023https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/1863023"},{"key":"ref24","doi-asserted-by":"publisher","unstructured":"Daya, S. and Berns, K. I. (2008) Gene therapy using adeno-associated virus vectors. Clinical Microbiology Reviews 21, 583-593.","DOI":"10.1128\/CMR.00008-0818854481https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/18854481"},{"key":"ref25","doi-asserted-by":"publisher","unstructured":"de Mendonca, L., Felix, N. S., Blanco, N. G., Da Silva, J. S., Ferreira, T. P., Abreu, S. C., Cruz, F. F., Rocha, N., Silva, P. M., Martins, V., Capelozzi, V. L., Zapata-Sudo, G., Rocco, P. R. M. and Silva, P. L. (2017) Mesenchymal stromal cell therapy reduces lung inflammation and vascular remodeling and improves hemodynamics in experimental pulmonary arterial hypertension. Stem Cell Research & Therapy 8, 220.","DOI":"10.1186\/s13287-017-0669-028974252https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/28974252"},{"key":"ref26","doi-asserted-by":"publisher","unstructured":"Denton, C. P., Pope, J. E., Peter, H. H., Gabrielli, A., Boonstra, A., van den Hoogen, F. H., Riemekasten, G., De Vita, S., Morganti, A., Dolberg, M., Berkani, O., Guillevin, L., Scleroderma, T. R. U. i. P. a. w. and Connective Tissue Diseases, I. (2008) Long-term effects of bosentan on quality of life, survival, safety and tolerability in pulmonary arterial hypertension related to connective tissue diseases. Annals of the Rheumatic Diseases 67, 1222-1228.","DOI":"10.1136\/ard.2007.07992118055477https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/18055477"},{"key":"ref27","doi-asserted-by":"publisher","unstructured":"Eckschlager, T., Plch, J., Stiborova, M. and Hrabeta, J. (2017) Histone Deacetylase Inhibitors as Anticancer Drugs. International Journal of Molecular Sciences 18, 1414","DOI":"10.3390\/ijms18071414http:\/\/www.mdpi.com\/1422-0067\/18\/7\/1414"},{"key":"ref28","doi-asserted-by":"publisher","unstructured":"Fessel, J. P., Loyd, J. E. and Austin, E. D. (2011) The genetics of pulmonary arterial hypertension in the post-BMPR2 era. Pulmonary Circulation 1, 305-319.","DOI":"10.4103\/2045-8932.8729322140620https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/22140620"},{"key":"ref29","doi-asserted-by":"crossref","unstructured":"Forstermann, U. and Sessa, W. C. (2012) Nitric oxide synthases: regulation and function. European Heart Journal 33, 829-837, 837a-837d.","DOI":"10.1093\/eurheartj\/ehr304"},{"key":"ref30","doi-asserted-by":"publisher","unstructured":"Foster, W. S., Suen, C. M. and Stewart, D. J. (2014) Regenerative cell and tissue-based therapies for pulmonary arterial hypertension. Canadian Journal of Cardiology 30, 1350-1360.","DOI":"10.1016\/j.cjca.2014.08.02225442435https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/25442435"},{"key":"ref31","doi-asserted-by":"publisher","unstructured":"Galie, N., Barbera, J. A., Frost, A. E., Ghofrani, H. A., Hoeper, M. M., McLaughlin, V. V., Peacock, A. J., Simonneau, G., Vachiery, J. L., Grunig, E., Oudiz, R. J., Vonk-Noordegraaf, A., White, R. J., Blair, C., Gillies, H., Miller, K. L., Harris, J. H., Langley, J., Rubin, L. J. and Investigators, A. (2015) Initial use of ambrisentan plus tadalafil in pulmonary arterial hypertension. New England Journal of Medicine 373, 834-844.","DOI":"10.1056\/NEJMoa141368726308684https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/26308684"},{"key":"ref32","doi-asserted-by":"publisher","unstructured":"Galie, N., Brundage, B. H., Ghofrani, H. A., Oudiz, R. J., Simonneau, G., Safdar, Z., Shapiro, S., White, R. J., Chan, M., Beardsworth, A., Frumkin, L., Barst, R. J., Pulmonary Arterial, H. and Response to Tadalafil Study, G. (2009) Tadalafil therapy for pulmonary arterial hypertension. Circulation 119, 2894-2903.","DOI":"10.1161\/CIRCULATIONAHA.108.83927419470885https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/19470885"},{"key":"ref33","doi-asserted-by":"publisher","unstructured":"Galie, N., Ghofrani, H. A., Torbicki, A., Barst, R. J., Rubin, L. J., Badesch, D., Fleming, T., Parpia, T., Burgess, G., Branzi, A., Grimminger, F., Kurzyna, M., Simonneau, G. and Sildenafil Use in Pulmonary Arterial Hypertension Study, G. (2005) Sildenafil citrate therapy for pulmonary arterial hypertension. New England Journal of Medicine 353, 2148-2157.","DOI":"10.1056\/NEJMoa05001016291984https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/16291984"},{"key":"ref34","doi-asserted-by":"publisher","unstructured":"Galie, N., Humbert, M., Vachiery, J. L., Gibbs, S., Lang, I., Torbicki, A., Simonneau, G., Peacock, A., Vonk Noordegraaf, A., Beghetti, M., Ghofrani, A., Gomez Sanchez, M. A., Hansmann, G., Klepetko, W., Lancellotti, P., Matucci, M., McDonagh, T., Pierard, L. A., Trindade, P. T., Zompatori, M., Hoeper, M. and Group, E. S. C. S. D. (2016) 2015 ESC\/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT). European Heart Journal 37, 67-119.","DOI":"10.1093\/eurheartj\/ehv31726320113https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/26320113"},{"key":"ref35","doi-asserted-by":"publisher","unstructured":"Galie, N., McLaughlin, V. V., Rubin, L. J. and Simonneau, G. (2019) An overview of the 6th World symposium on pulmonary hypertension. European Respiratory Journal 53, 1802148.","DOI":"10.1183\/13993003.02148-201830552088https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/30552088"},{"key":"ref36","doi-asserted-by":"crossref","unstructured":"Galie, N., Olschewski, H., Oudiz, R. J., Torres, F., Frost, A., Ghofrani, H. A., Badesch, D. B., McGoon, M. D., McLaughlin, V. V., Roecker, E. B., Gerber, M. J., Dufton, C., Wiens, B. L., Rubin, L. J. and Ambrisentan in Pulmonary Arterial Hypertension, R. D.-B. P.-C. M. E. S. G. (2008) Ambrisentan for the treatment of pulmonary arterial hypertension: results of the ambrisentan in pulmonary arterial hypertension, randomized, double-blind, placebo-controlled, multicenter, efficacy (ARIES) study 1 and 2. Circulation 117, 3010-3019. 18506008https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/18506008","DOI":"10.1161\/CIRCULATIONAHA.107.742510"},{"key":"ref37","doi-asserted-by":"publisher","unstructured":"Ghofrani, H. A., Barst, R. J., Benza, R. L., Champion, H. C., Fagan, K. A., Grimminger, F., Humbert, M., Simonneau, G., Stewart, D. J., Ventura, C. and Rubin, L. J. (2009) Future perspectives for the treatment of pulmonary arterial hypertension. Journal of the American College of Cardiology 54, S108-117.","DOI":"10.1016\/j.jacc.2009.04.01419555854https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/19555854"},{"key":"ref38","doi-asserted-by":"publisher","unstructured":"Ghofrani, H. A., Galie, N., Grimminger, F., Grunig, E., Humbert, M., Jing, Z. C., Keogh, A. M., Langleben, D., Kilama, M. O., Fritsch, A., Neuser, D., Rubin, L. J. and Group, P.-S. (2013) Riociguat for the treatment of pulmonary arterial hypertension. New England Journal of Medicine 369, 330-340.","DOI":"10.1056\/NEJMoa120965523883378https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/23883378"},{"key":"ref39","doi-asserted-by":"crossref","unstructured":"Ghofrani, H. A., Hoeper, M. M., Halank, M., Meyer, F. J., Staehler, G., Behr, J., Ewert, R., Weimann, G. and Grimminger, F. (2010) Riociguat for chronic thromboembolic pulmonary hypertension and pulmonary arterial hypertension: a phase II study. European Respiratory Journal 36, 792-799. 20530034https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/20530034","DOI":"10.1183\/09031936.00182909"},{"key":"ref40","doi-asserted-by":"publisher","unstructured":"Gomberg-Maitland, M. and Olschewski, H. (2008) Prostacyclin therapies for the treatment of pulmonary arterial hypertension. European Respiratory Journal 31, 891-901.","DOI":"10.1183\/09031936.0009710718378784https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/18378784"},{"key":"ref41","doi-asserted-by":"publisher","unstructured":"Granton, J., Langleben, D., Kutryk, M. B., Camack, N., Galipeau, J., Courtman, D. W. and Stewart, D. J. (2015) Endothelial NO-Synthase Gene-Enhanced Progenitor Cell Therapy for Pulmonary Arterial Hypertension: The PHACeT Trial. Circulation Research 117, 645-654.","DOI":"10.1161\/CIRCRESAHA.114.30595126195220https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/26195220"},{"key":"ref42","doi-asserted-by":"publisher","unstructured":"Gu, M., Shao, N. Y., Sa, S., Li, D., Termglinchan, V., Ameen, M., Karakikes, I., Sosa, G., Grubert, F., Lee, J., Cao, A., Taylor, S., Ma, Y., Zhao, Z., Chappell, J., Hamid, R., Austin, E. D., Gold, J. D., Wu, J. C., Snyder, M. P. and Rabinovitch, M. (2017) Patient-specific iPSC-derived endothelial cells uncover pathways that protect against pulmonary hypertension in BMPR2 mutation carriers. Cell Stem Cell 20, 490-504 e495.","DOI":"10.1016\/j.stem.2016.08.01928017794https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/28017794"},{"key":"ref43","doi-asserted-by":"crossref","unstructured":"Hadri, L., Kratlian, R. G., Benard, L., Maron, B. A., Dorfmuller, P., Ladage, D., Guignabert, C., Ishikawa, K., Aguero, J., Ibanez, B., Turnbull, I. C., Kohlbrenner, E., Liang, L., Zsebo, K., Humbert, M., Hulot, J. S., Kawase, Y., Hajjar, R. J. and Leopold, J. A. (2013) Therapeutic efficacy of AAV1.SERCA2a in monocrotaline-induced pulmonary arterial hypertension. Circulation 128, 512-523. 23804254https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/23804254","DOI":"10.1161\/CIRCULATIONAHA.113.001585"},{"key":"ref44","doi-asserted-by":"publisher","unstructured":"Harper, R. L., Maiolo, S., Ward, R. J., Seyfang, J., Cockshell, M. P., Bonder, C. S. and Reynolds, P. N. (2019) BMPR2-expressing bone marrow-derived endothelial-like progenitor cells alleviate pulmonary arterial hypertension in vivo. Respirology 24, 1095-1103.","DOI":"10.1111\/resp.1355230977250https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/30977250"},{"key":"ref45","doi-asserted-by":"publisher","unstructured":"Huang, W. C., Ke, M. W., Cheng, C. C., Chiou, S. H., Wann, S. R., Shu, C. W., Chiou, K. R., Tseng, C. J., Pan, H. W., Mar, G. Y. and Liu, C. P. (2016) Therapeutic benefits of induced pluripotent stem cells in monocrotaline-induced pulmonary arterial hypertension. PLoS One 11, e0142476.","DOI":"10.1371\/journal.pone.014247626840075https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/26840075"},{"key":"ref46","doi-asserted-by":"publisher","unstructured":"Hynynen, M. M. and Khalil, R. A. (2006) The vascular endothelin system in hypertension--recent patents and discoveries. Recent Patents on Cardiovascular Drug Discovery 1, 95-108.","DOI":"10.2174\/15748900677524426317200683https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/17200683"},{"key":"ref47","doi-asserted-by":"crossref","unstructured":"Jing, Z. C., Yu, Z. X., Shen, J. Y., Wu, B. X., Xu, K. F., Zhu, X. Y., Pan, L., Zhang, Z. L., Liu, X. Q., Zhang, Y. S., Jiang, X., Galie, N., Efficacy and Safety of Vardenafil in the Treatment of Pulmonary Arterial Hypertension Study, G. (2011) Vardenafil in pulmonary arterial hypertension: a randomized, double-blind, placebo-controlled study. American Journal of Respiratory and Critical Care Medicine 183, 1723-1729. 21471085https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/21471085","DOI":"10.1164\/rccm.201101-0093OC"},{"key":"ref48","doi-asserted-by":"publisher","unstructured":"Kanki-Horimoto, S., Horimoto, H., Mieno, S., Kishida, K., Watanabe, F., Furuya, E. and Katsumata, T. (2006) Implantation of mesenchymal stem cells overexpressing endothelial nitric oxide synthase improves right ventricular impairments caused by pulmonary hypertension. Circulation 114, I181-185.","DOI":"10.1161\/CIRCULATIONAHA.105.00148716820570https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/16820570"},{"key":"ref49","doi-asserted-by":"publisher","unstructured":"Kass, D. A. and Solaro, R. J. (2006) Mechanisms and use of calcium-sensitizing agents in the failing heart. Circulation 113, 305-315.","DOI":"10.1161\/CIRCULATIONAHA.105.54240716418450https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/16418450"},{"key":"ref50","doi-asserted-by":"publisher","unstructured":"Katz, M. G., Fargnoli, A. S., Gubara, S. M., Fish, K., Weber, T., Bridges, C. R., Hajjar, R. J. and Ishikawa, K. (2019) Targeted Gene Delivery through the Respiratory System: Rationale for Intratracheal Gene Transfer. Journal of Cardiovascular Development and Disease 6, 8.","DOI":"10.3390\/jcdd6010008http:\/\/www.mdpi.com\/2308-3425\/6\/1\/8"},{"key":"ref51","doi-asserted-by":"publisher","unstructured":"Kim, J., Hwangbo, C., Hu, X., Kang, Y., Papangeli, I., Mehrotra, D., Park, H., Ju, H., McLean, D. L., Comhair, S. A., Erzurum, S. C. and Chun, H. J. (2015) Restoration of impaired endothelial myocyte enhancer factor 2 function rescues pulmonary arterial hypertension. Circulation 131, 190-199.","DOI":"10.1161\/CIRCULATIONAHA.114.01333925336633https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/25336633"},{"key":"ref52","doi-asserted-by":"publisher","unstructured":"Lai, Y. C., Potoka, K. C., Champion, H. C., Mora, A. L. and Gladwin, M. T. (2014) Pulmonary arterial hypertension: the clinical syndrome. Circulation Research 115, 115-130.","DOI":"10.1161\/CIRCRESAHA.115.3011467fd5387c-1925-4a5f-9061-736b6fb2fde6http:\/\/dx.doi.org\/10.1161\/CIRCRESAHA.115.301146"},{"key":"ref53","doi-asserted-by":"crossref","unstructured":"Lalu, M. M., McIntyre, L., Pugliese, C., Fergusson, D., Winston, B. W., Marshall, J. C., Granton, J., Stewart, D. J. and Canadian Critical Care Trials, G. (2012) Safety of cell therapy with mesenchymal stromal cells (SafeCell): a systematic review and meta-analysis of clinical trials. PLoS One 7, e47559. 23133515https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/23133515","DOI":"10.1371\/journal.pone.0047559"},{"key":"ref54","doi-asserted-by":"publisher","unstructured":"Lambert, O. and Bandilla, D. (2012) Stability and preservation of a new formulation of epoprostenol sodium for treatment of pulmonary arterial hypertension. Drug Design, Development and Therapy 6, 235-244.","DOI":"10.2147\/DDDT.S3162823049244https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/23049244"},{"key":"ref55","doi-asserted-by":"publisher","unstructured":"Lee, C., Mitsialis, S. A., Aslam, M., Vitali, S. H., Vergadi, E., Konstantinou, G., Sdrimas, K., Fernandez-Gonzalez, A. and Kourembanas, S. (2012) Exosomes mediate the cytoprotective action of mesenchymal stromal cells on hypoxia-induced pulmonary hypertension. Circulation 126, 2601-2611.","DOI":"10.1161\/CIRCULATIONAHA.112.114173231147893f0fa564-31da-4c14-868f-b4d151107bc3https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/23114789"},{"key":"ref56","doi-asserted-by":"publisher","unstructured":"Lee, C. S., Bishop, E. S., Zhang, R., Yu, X., Farina, E. M., Yan, S., Zhao, C., Zheng, Z., Shu, Y., Wu, X., Lei, J., Li, Y., Zhang, W., Yang, C., Wu, K., Wu, Y., Ho, S., Athiviraham, A., Lee, M. J., Wolf, J. M., Reid, R. R. and He, T. C. (2017) Adenovirus-Mediated Gene Delivery: Potential Applications for Gene and Cell-Based Therapies in the New Era of Personalized Medicine. Genes & Diseases 4, 43-63.","DOI":"10.1016\/j.gendis.2017.04.00128944281https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/28944281"},{"key":"ref57","doi-asserted-by":"publisher","unstructured":"Lee, T. I. and Young, R. A. (2013) Transcriptional regulation and its misregulation in disease. Cell 152, 1237-1251.","DOI":"10.1016\/j.cell.2013.02.01423498934https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/23498934"},{"key":"ref58","doi-asserted-by":"crossref","unstructured":"Liang, O. D., Mitsialis, S. A., Chang, M. S., Vergadi, E., Lee, C., Aslam, M., Fernandez-Gonzalez, A., Liu, X., Baveja, R. and Kourembanas, S. (2011) Mesenchymal stromal cells expressing heme oxygenase-1 reverse pulmonary hypertension. Stem Cells 29, 99-107. 20957739https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/20957739","DOI":"10.1002\/stem.548"},{"key":"ref59","doi-asserted-by":"publisher","unstructured":"Liu, D., Yan, Y., Chen, J. W., Yuan, P., Wang, X. J., Jiang, R., Wang, L., Zhao, Q. H., Wu, W. H., Simonneau, G., Qu, J. M. and Jing, Z. C. (2017) Hypermethylation of BMPR2 promoter occurs in patients with heritable pulmonary arterial hypertension and inhibits BMPR2 expression. American Journal of Respiratory and Critical Care Medicine 196, 925-928.","DOI":"10.1164\/rccm.201611-2273LE28170297https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/28170297"},{"key":"ref60","doi-asserted-by":"publisher","unstructured":"Liu, Z., Wang, P., Chen, H., Wold, E. A., Tian, B., Brasier, A. R. and Zhou, J. (2017) Drug discovery targeting bromodomain-containing protein 4. Journal of Medicinal Chemistry 60, 4533-4558.","DOI":"10.1021\/acs.jmedchem.6b0176128195723https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/28195723"},{"key":"ref61","doi-asserted-by":"publisher","unstructured":"Loisel, F., Provost, B., Haddad, F., Guihaire, J., Amsallem, M., Vrtovec, B., Fadel, E., Uzan, G. and Mercier, O. (2018) Stem cell therapy targeting the right ventricle in pulmonary arterial hypertension: is it a potential avenue of therapy? Pulmonary Circulation 8, 2045893218755979.","DOI":"10.1177\/204589321875597929480154https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/29480154"},{"key":"ref62","doi-asserted-by":"publisher","unstructured":"Long, L., Ormiston, M. L., Yang, X., Southwood, M., Graf, S., Machado, R. D., Mueller, M., Kinzel, B., Yung, L. M., Wilkinson, J. M., Moore, S. D., Drake, K. M., Aldred, M. A., Yu, P. B., Upton, P. D. and Morrell, N. W. (2015) Selective enhancement of endothelial BMPR-II with BMP9 reverses pulmonary arterial hypertension. Nature Medicine 21, 777-785.","DOI":"10.1038\/nm.387726076038https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/26076038"},{"key":"ref63","doi-asserted-by":"crossref","unstructured":"Mahla, R. S.(2016) Stem Cells applications in regenerative medicine and disease therapeutics. International Journal of Cell Biology 2016,6940283.","DOI":"10.1155\/2016\/6940283"},{"key":"ref64","doi-asserted-by":"publisher","unstructured":"Majed, B. H. and Khalil, R. A. (2012) Molecular mechanisms regulating the vascular prostacyclin pathways and their adaptation during pregnancy and in the newborn. Pharmacological Reviews 64, 540-582.","DOI":"10.1124\/pr.111.0047705f8f8cea-1874-4807-a3ce-df7131544890http:\/\/dx.doi.org\/10.1124\/pr.111.004770"},{"key":"ref65","doi-asserted-by":"publisher","unstructured":"McGoon, M. D. and Miller, D. P. (2012) REVEAL: a contemporary US pulmonary arterial hypertension registry. European Respiratory Review 21, 8-18.","DOI":"10.1183\/09059180.0000821122379169https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/22379169"},{"key":"ref66","doi-asserted-by":"publisher","unstructured":"McLaughlin, V. V., Benza, R. L., Rubin, L. J., Channick, R. N., Voswinckel, R., Tapson, V. F., Robbins, I. M., Olschewski, H., Rubenfire, M. and Seeger, W. (2010) Addition of inhaled treprostinil to oral therapy for pulmonary arterial hypertension: a randomized controlled clinical trial. Journal of the American College of Cardiology 55, 1915-1922.","DOI":"10.1016\/j.jacc.2010.01.0273d481c37-c95d-4450-bac3-a9049349007ahttp:\/\/www.sciencedirect.com\/science\/article\/pii\/S0735109710007795"},{"key":"ref67","doi-asserted-by":"crossref","unstructured":"McLaughlin, V. V., Oudiz, R. J., Frost, A., Tapson, V. F., Murali, S., Channick, R. N., Badesch, D. B., Barst, R. J., Hsu, H. H. and Rubin, L. J. (2006) Randomized study of adding inhaled iloprost to existing bosentan in pulmonary arterial hypertension. American Journal of Respiratory and Critical Care Medicine 174, 1257-1263. 16946127https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/16946127","DOI":"10.1164\/rccm.200603-358OC"},{"key":"ref68","doi-asserted-by":"publisher","unstructured":"Meloche, J., Potus, F., Vaillancourt, M., Bourgeois, A., Johnson, I., Deschamps, L., Chabot, S., Ruffenach, G., Henry, S., Breuils-Bonnet, S., Tremblay, E., Nadeau, V., Lambert, C., Paradis, R., Provencher, S. and Bonnet, S. (2015) Bromodomain-containing protein 4: the epigenetic origin of pulmonary arterial hypertension. Circulation Research 117, 525-535.","DOI":"10.1161\/CIRCRESAHA.115.30700426224795https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/26224795"},{"key":"ref69","doi-asserted-by":"publisher","unstructured":"Mingozzi, F. and High, K. A. (2013) Immune responses to AAV vectors: overcoming barriers to successful gene therapy. Blood 122, 23-36.","DOI":"10.1182\/blood-2013-01-30664723596044https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/23596044"},{"key":"ref70","doi-asserted-by":"publisher","unstructured":"Montani, D., Chaumais, M. C., Savale, L., Natali, D., Price, L. C., Jais, X., Humbert, M., Simonneau, G. and Sitbon, O. (2009) Phosphodiesterase type 5 inhibitors in pulmonary arterial hypertension. Advances in Therapy 26, 813-825.","DOI":"10.1007\/s12325-009-0064-z4465a9d0-db41-4e2e-9e40-eb1cd670ddc8http:\/\/www.springerlink.com\/content\/x124572g726124j8\/"},{"key":"ref71","doi-asserted-by":"publisher","unstructured":"Montani, D., Gunther, S., Dorfmuller, P., Perros, F., Girerd, B., Garcia, G., Jais, X., Savale, L., Artaud-Macari, E., Price, L. C., Humbert, M., Simonneau, G. and Sitbon, O. (2013) Pulmonary arterial hypertension. Orphanet Journal of Rare Diseases 8, 97.","DOI":"10.1186\/1750-1172-8-9723829793https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/23829793"},{"key":"ref72","doi-asserted-by":"publisher","unstructured":"Muller, S., Filippakopoulos, P. and Knapp, S. (2011) Bromodomains as therapeutic targets. Expert Expert Reviews in Molecular Medicine 13, e29.","DOI":"10.1017\/S146239941100199221933453https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/21933453"},{"key":"ref73","doi-asserted-by":"publisher","unstructured":"Naso, M. F., Tomkowicz, B., Perry, W. L., 3rd and Strohl, W. R. (2017) Adeno-Associated Virus (AAV) as a Vector for Gene Therapy. BioDrugs 31, 317-334.","DOI":"10.1007\/s40259-017-0234-528669112https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/28669112"},{"key":"ref74","unstructured":"Nieminen, M. S., Fruhwald, S., Heunks, L. M., Suominen, P. K., Gordon, A. C., Kivikko, M. and Pollesello, P. (2013) Levosimendan: current data, clinical use and future development. Heart Lung Vessel 5, 227-245. 24364017https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/24364017"},{"key":"ref75","doi-asserted-by":"publisher","unstructured":"Olschewski, H., Simonneau, G., Galie, N., Higenbottam, T., Naeije, R., Rubin, L. J., Nikkho, S., Speich, R., Hoeper, M. M., Behr, J., Winkler, J., Sitbon, O., Popov, W., Ghofrani, H. A., Manes, A., Kiely, D. G., Ewert, R., Meyer, A., Corris, P. A., Delcroix, M., Gomez-Sanchez, M., Siedentop, H., Seeger, W. and Aerosolized Iloprost Randomized Study, G. (2002) Inhaled iloprost for severe pulmonary hypertension. New England Journal of Medicine 347, 322-329.","DOI":"10.1056\/NEJMoa02020412151469https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/12151469"},{"key":"ref76","doi-asserted-by":"publisher","unstructured":"Oudiz, R. J., Brundage, B. H., Galie, N., Ghofrani, H. A., Simonneau, G., Botros, F. T., Chan, M., Beardsworth, A., Barst, R. J. and Group, P. S. (2012) Tadalafil for the treatment of pulmonary arterial hypertension: a double-blind 52-week uncontrolled extension study. Journal of the American College of Cardiology 60, 768-774.","DOI":"10.1016\/j.jacc.2012.05.004f4e9bedb-16d7-4582-a5d9-9135a30a44edhttp:\/\/dx.doi.org\/10.1016\/j.jacc.2012.05.004"},{"key":"ref77","doi-asserted-by":"crossref","unstructured":"Oudiz, R. J., Galie, N., Olschewski, H., Torres, F., Frost, A., Ghofrani, H. A., Badesch, D. B., McGoon, M. D., McLaughlin, V. V., Roecker, E. B., Harrison, B. C., Despain, D., Dufton, C., Rubin, L. J. and Group, A. S. (2009) Long-term ambrisentan therapy for the treatment of pulmonary arterial hypertension. Journal of the American College of Cardiology 54, 1971-1981. 19909879https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/19909879","DOI":"10.1016\/j.jacc.2009.07.033"},{"key":"ref78","doi-asserted-by":"crossref","unstructured":"Pfeifer, A. and Verma, I. M. (2001) Gene therapy: promises and problems. Annual Review of Genomics and Human Genetics 2, 177-211. 11701648https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/11701648","DOI":"10.1146\/annurev.genom.2.1.177"},{"key":"ref79","doi-asserted-by":"publisher","unstructured":"Pulido, T., Adzerikho, I., Channick, R. N., Delcroix, M., Galie, N., Ghofrani, H. A., Jansa, P., Jing, Z. C., Le Brun, F. O., Mehta, S., Mittelholzer, C. M., Perchenet, L., Sastry, B. K., Sitbon, O., Souza, R., Torbicki, A., Zeng, X., Rubin, L. J., Simonneau, G. and Investigators, S. (2013) Macitentan and morbidity and mortality in pulmonary arterial hypertension. New England Journal of Medicine 369, 809-818.","DOI":"10.1056\/NEJMoa121391723984728https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/23984728"},{"key":"ref80","doi-asserted-by":"publisher","unstructured":"Pullamsetti, S. S. and de Jesus Perez, V. A. (2019) EpiHope for the treatment of pulmonary arterial hypertension: selective versus nonselective BET inhibition. American Journal of Respiratory and Critical Care Medicine 200, 1188-1190.","DOI":"10.1164\/rccm.201906-1235LE31419389https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/31419389"},{"key":"ref81","doi-asserted-by":"crossref","unstructured":"Ranganath, S. H., Levy, O., Inamdar, M. S. and Karp, J. M. (2012) Harnessing the mesenchymal stem cell secretome for the treatment of cardiovascular disease. Cell Stem Cell 10, 244-258. 22385653https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/22385653","DOI":"10.1016\/j.stem.2012.02.005"},{"key":"ref82","doi-asserted-by":"crossref","unstructured":"Reynolds, A. M., Xia, W., Holmes, M. D., Hodge, S. J., Danilov, S., Curiel, D. T., Morrell, N. W. and Reynolds, P. N. (2007) Bone morphogenetic protein type 2 receptor gene therapy attenuates hypoxic pulmonary hypertension. American Journal of Physiology-Lung Cellular and Molecular Physiology 292, L1182-1192. 17277049https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/17277049","DOI":"10.1152\/ajplung.00020.2006"},{"key":"ref83","doi-asserted-by":"publisher","unstructured":"Reynolds, P. N. (2011) Gene therapy for pulmonary hypertension: prospects and challenges. Expert Opinion on Biological Therapy 11, 133-143.","DOI":"10.1517\/14712598.2011.5421392121923226aec5c1-5a50-4bf1-8b0f-e3cf0a615034http:\/\/dx.doi.org\/10.1517\/14712598.2011.542139"},{"key":"ref84","doi-asserted-by":"publisher","unstructured":"Rubin, L. J., Badesch, D. B., Barst, R. J., Galie, N., Black, C. M., Keogh, A., Pulido, T., Frost, A., Roux, S., Leconte, I., Landzberg, M. and Simonneau, G. (2002) Bosentan therapy for pulmonary arterial hypertension. New England Journal of Medicine 346, 896-903.","DOI":"10.1056\/NEJMoa01221211907289https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/11907289"},{"key":"ref85","doi-asserted-by":"crossref","unstructured":"Rubin, L. J., Badesch, D. B., Fleming, T. R., Galie, N., Simonneau, G., Ghofrani, H. A., Oakes, M., Layton, G., Serdarevic-Pehar, M., McLaughlin, V. V., Barst, R. J. and Group, S.-S. (2011) Long-term treatment with sildenafil citrate in pulmonary arterial hypertension: the SUPER-2 study. Chest 140, 1274-1283. 21546436https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/21546436","DOI":"10.1378\/chest.10-0969"},{"key":"ref86","doi-asserted-by":"crossref","unstructured":"Rubin, L. J., Mendoza, J., Hood, M., McGoon, M., Barst, R., Williams, W. B., Diehl, J. H., Crow, J. and Long, W. (1990) Treatment of primary pulmonary hypertension with continuous intravenous prostacyclin (epoprostenol). Results of a randomized trial. Annals of Internal Medicine 112, 485-491. 2107780https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/2107780","DOI":"10.7326\/0003-4819-112-7-485"},{"key":"ref87","doi-asserted-by":"publisher","unstructured":"Sakao, S Tatsumi, K. and Voelkel, N. F. (2009) Endothelial cells and pulmonary arterial hypertension: apoptosis, proliferation, interaction and transdifferentiation. Respiratory Research 10, 95.","DOI":"10.1186\/1465-9921-10-9519825167https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/19825167"},{"key":"ref88","doi-asserted-by":"publisher","unstructured":"Seto, E. and Yoshida, M. (2014) Erasers of histone acetylation: the histone deacetylase enzymes. Cold Spring Harbor Perspectives in Biology 6, a018713.","DOI":"10.1101\/cshperspect.a01871324691964https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/24691964"},{"key":"ref89","doi-asserted-by":"publisher","unstructured":"Shimoda, L. A. and Laurie, S. S. (2013) Vascular remodeling in pulmonary hypertension. Journal of Molecular Medicine 91, 297-309.","DOI":"10.1007\/s00109-013-0998-023334338https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/23334338"},{"key":"ref90","doi-asserted-by":"publisher","unstructured":"Simonneau, G., Barst, R. J., Galie, N., Naeije, R., Rich, S., Bourge, R. C., Keogh, A., Oudiz, R., Frost, A., Blackburn, S. D., Crow, J. W., Rubin, L. J. and Treprostinil Study, G. (2002) Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: a double-blind, randomized, placebo-controlled trial. American Journal of Respiratory and Critical Care Medicine 165, 800-804.","DOI":"10.1164\/ajrccm.165.6.210607911897647https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/11897647"},{"key":"ref91","doi-asserted-by":"publisher","unstructured":"Simonneau, G., Gatzoulis, M. A., Adatia, I., Celermajer, D., Denton, C., Ghofrani, A., Gomez Sanchez, M. A., Krishna Kumar, R., Landzberg, M., Machado, R. F., Olschewski, H., Robbins, I. M. and Souza, R. (2013) Updated clinical classification of pulmonary hypertension. Journal of the American College of Cardiology 62, D34-41.","DOI":"10.1016\/j.jacc.2013.10.02924355639https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/24355639"},{"key":"ref92","doi-asserted-by":"publisher","unstructured":"Simonneau, G., Rubin, L. J., Galie, N., Barst, R. J., Fleming, T. R., Frost, A. E., Engel, P. J., Kramer, M. R., Burgess, G., Collings, L., Cossons, N., Sitbon, O., Badesch, D. B. and Group, P. S. (2008) Addition of sildenafil to long-term intravenous epoprostenol therapy in patients with pulmonary arterial hypertension: a randomized trial. Annals of Internal Medicine 149, 521-530.","DOI":"10.7326\/0003-4819-149-8-200810210-0000418936500https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/18936500"},{"key":"ref93","doi-asserted-by":"crossref","unstructured":"Sitbon, O., Channick, R., Chin, K. M., Frey, A., Gaine, S., Galie, N., Ghofrani, H. A., Hoeper, M. M., Lang, I. M., Preiss, R., Rubin, L. J., Di Scala, L., Tapson, V., Adzerikho, I., Liu, J., Moiseeva, O., Zeng, X., Simonneau, G., McLaughlin, V. V. and Investigators, G. (2015) Selexipag for the Treatment of Pulmonary Arterial Hypertension. New England Journal of Medicine 373, 2522-2533. 26699168https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/26699168","DOI":"10.1056\/NEJMoa1503184"},{"key":"ref94","doi-asserted-by":"publisher","unstructured":"Sitbon, O. and Morrell, N. (2012) Pathways in pulmonary arterial hypertension: the future is here. European Respiratory Rev 21, 321-327.","DOI":"10.1183\/09059180.00004812http:\/\/err.ersjournals.com\/cgi\/doi\/10.1183\/09059180.00004812"},{"key":"ref95","doi-asserted-by":"publisher","unstructured":"Sitbon, O. and Vonk Noordegraaf, A. (2017) Epoprostenol and pulmonary arterial hypertension: 20 years of clinical experience. European Respiratory Review 26,","DOI":"10.1183\/16000617.0061-201729070579https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/29070579"},{"key":"ref96","doi-asserted-by":"publisher","unstructured":"Spiekerkoetter, E., Sung, Y. K., Sudheendra, D., Bill, M., Aldred, M. A., van de Veerdonk, M. C., Vonk Noordegraaf, A., Long-Boyle, J., Dash, R., Yang, P. C., Lawrie, A., Swift, A. J., Rabinovitch, M. and Zamanian, R. T. (2015) Low-Dose FK506 (Tacrolimus) in End-Stage Pulmonary Arterial Hypertension. American Journal of Respiratory and Critical Care Medicine 192, 254-257.","DOI":"10.1164\/rccm.201411-2061LE26177174https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/26177174"},{"key":"ref97","doi-asserted-by":"crossref","unstructured":"Spiekerkoetter, E., Tian, X., Cai, J., Hopper, R. K., Sudheendra, D., Li, C. G., El-Bizri, N., Sawada, H., Haghighat, R., Chan, R., Haghighat, L., de Jesus Perez, V., Wang, L., Reddy, S., Zhao, M., Bernstein, D., Solow-Cordero, D. E., Beachy, P. A., Wandless, T. J., Ten Dijke, P. and Rabinovitch, M. (2013) FK506 activates BMPR2, rescues endothelial dysfunction, and reverses pulmonary hypertension. Journal of Clinical Investigation 123, 3600-3613. 23867624https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/23867624","DOI":"10.1172\/JCI65592"},{"key":"ref98","doi-asserted-by":"publisher","unstructured":"Stamm, J. A., Risbano, M. G. and Mathier, M. A. (2011) Overview of current therapeutic approaches for pulmonary hypertension. Pulmonary Circulation 1, 138-159.","DOI":"10.4103\/2045-8932.8344422034603https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/22034603"},{"key":"ref99","doi-asserted-by":"crossref","unstructured":"Strauss, B., Sassi, Y., Bueno-Beti, C., Ilkan, Z., Raad, N., Cacheux, M., Bisserier, M., Turnbull, I. C., Kohlbrenner, E., Hajjar, R. J., Hadri, L. and Akar, F. G. (2019) Intra-tracheal gene delivery of aerosolized SERCA2a to the lung suppresses ventricular arrhythmias in a model of pulmonary arterial hypertension. Journal of Molecular and Cellular Cardiology 127, 20-30. 30502350https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/30502350","DOI":"10.1016\/j.yjmcc.2018.11.017"},{"key":"ref100","doi-asserted-by":"publisher","unstructured":"Suen, C. M., Mei, S. H., Kugathasan, L. and Stewart, D. J. (2013) Targeted delivery of genes to endothelial cells and cell- and gene-based therapy in pulmonary vascular diseases. Comprehensive Physiology 3, 1749-1779.","DOI":"10.1002\/cphy.c12003424265244https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/24265244"},{"key":"ref101","doi-asserted-by":"publisher","unstructured":"Tapson, V. F., Gomberg-Maitland, M., McLaughlin, V. V., Benza, R. L., Widlitz, A. C., Krichman, A. and Barst, R. J. (2006) Safety and efficacy of IV treprostinil for pulmonary arterial hypertension: a prospective, multicenter, open-label, 12-week trial. Chest 129, 683-688.","DOI":"10.1378\/chest.129.3.68316537868https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/16537868"},{"key":"ref102","doi-asserted-by":"publisher","unstructured":"Umar, S., de Visser, Y. P., Steendijk, P., Schutte, C. I., Laghmani el, H., Wagenaar, G. T., Bax, W. H., Mantikou, E., Pijnappels, D. A., Atsma, D. E., Schalij, M. J., van der Wall, E. E. and van der Laarse, A. (2009) Allogenic stem cell therapy improves right ventricular function by improving lung pathology in rats with pulmonary hypertension. American Journal of Physiology: Heart and Circulatory Physiology 297, H1606-1616.","DOI":"10.1152\/ajpheart.00590.200919783775https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/19783775"},{"key":"ref103","doi-asserted-by":"crossref","unstructured":"Van der Feen, D. E., Kurakula, K., Tremblay, E., Boucherat, O., Bossers, G. P. L., Szulcek, R., Bourgeois, A., Lampron, M. C., Habbout, K., Martineau, S., Paulin, R., Kulikowski, E., Jahagirdar, R., Schalij, I., Bogaard, H. J., Bartelds, B., Provencher, S., Berger, R. M. F., Bonnet, S. and Goumans, M. J. (2019) Multicenter Preclinical Validation of BET Inhibition for the Treatment of Pulmonary Arterial Hypertension. American Journal of Respiratory and Critical Care Medicine 200, 910-920. 31042405https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/31042405","DOI":"10.1164\/rccm.201812-2275OC"},{"key":"ref104","doi-asserted-by":"crossref","unstructured":"Ventetuolo, C. E. and Klinger, J. R. (2012) WHO Group 1 pulmonary arterial hypertension: current and investigative therapies. Progress in Cardiovascular Diseases 55, 89-103. 23009906https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/23009906","DOI":"10.1016\/j.pcad.2012.07.002"},{"key":"ref105","unstructured":"Via, A. G., Frizziero, A. and Oliva, F. (2012) Biological properties of mesenchymal Stem Cells from different sources. Muscle, Ligaments and Tendons Journal 2, 154-162."},{"key":"ref106","doi-asserted-by":"publisher","unstructured":"Wang, X. X., Zhang, F. R., Shang, Y. P., Zhu, J. H., Xie, X. D., Tao, Q. M., Zhu, J. H. and Chen, J. Z. (2007) Transplantation of autologous endothelial progenitor cells may be beneficial in patients with idiopathic pulmonary arterial hypertension: a pilot randomized controlled trial. Journal of the American College of Cardiology 49, 1566-1571.","DOI":"10.1016\/j.jacc.2006.12.03717418297https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/17418297"},{"key":"ref107","doi-asserted-by":"crossref","unstructured":"Watanabe, S., Ishikawa, K., Plataki, M., Bikou, O., Kohlbrenner, E., Aguero, J., Hadri, L., Zarragoikoetxea, I., Fish, K., Leopold, J. A. and Hajjar, R. J. (2018) Safety and long-term efficacy of AAV1.SERCA2a using nebulizer delivery in a pig model of pulmonary hypertension. Pulmonary Circulation 8, 2045894018799738. 30129881https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/30129881","DOI":"10.1177\/2045894018799738"},{"key":"ref108","doi-asserted-by":"crossref","unstructured":"Wei, A., Gu, Z., Li, J., Liu, X., Wu, X., Han, Y. and Pu, J. (2016) Clinical Adverse Effects of Endothelin Receptor Antagonists: Insights From the Meta-Analysis of 4894 Patients From 24 Randomized Double-Blind placebo-Controlled Clinical Trials. Journal of the American Heart Association 5, 27998918https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/27998918","DOI":"10.1161\/JAHA.116.003896"},{"key":"ref109","doi-asserted-by":"publisher","unstructured":"Weinhold, B. (2006) Epigenetics: the science of change. Environ Health Perspect 114, A160-167.","DOI":"10.1289\/ehp.114-a16016507447https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/16507447"},{"key":"ref110","doi-asserted-by":"crossref","unstructured":"Weiss, D. J., Bertoncello, I., Borok, Z., Kim, C., Panoskaltsis-Mortari, A., Reynolds, S., Rojas, M., Stripp, B., Warburton, D. and Prockop, D. J. (2011) Stem cells and cell therapies in lung biology and lung diseases. Proceedings of the American Thoracic Society 8, 223-272. 21653527https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/21653527","DOI":"10.1513\/pats.201012-071DW"},{"key":"ref111","doi-asserted-by":"publisher","unstructured":"Wharton, J., Strange, J. W., Moller, G. M., Growcott, E. J., Ren, X., Franklyn, A. P., Phillips, S. C. and Wilkins, M. R. (2005) Antiproliferative effects of phosphodiesterase type 5 inhibition in human pulmonary artery cells. American Journal of Respiratory and Critical Care Medicine 172, 105-113.","DOI":"10.1164\/rccm.200411-1587OC15817798https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/15817798"},{"key":"ref112","doi-asserted-by":"publisher","unstructured":"Wilkins, M. R., Wharton, J., Grimminger, F. and Ghofrani, H. A. (2008) Phosphodiesterase inhibitors for the treatment of pulmonary hypertension. European Respiratory Journal 32, 198-209.","DOI":"10.1183\/09031936.0012400718591337https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/18591337"},{"key":"ref113","doi-asserted-by":"publisher","unstructured":"Yoder, M. C. (2012) Human endothelial progenitor cells. Cold Spring Harbor Perspectives in Medicine 2, a006692.","DOI":"10.1101\/cshperspect.a00669222762017https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/22762017"},{"key":"ref114","doi-asserted-by":"crossref","unstructured":"Zhao, L., Chen, C. N., Hajji, N., Oliver, E., Cotroneo, E., Wharton, J., Wang, D., Li, M., McKinsey, T. A., Stenmark, K. R. and Wilkins, M. R. (2012) Histone deacetylation inhibition in pulmonary hypertension: therapeutic potential of valproic acid and suberoylanilide hydroxamic acid. Circulation 126, 455-467. 22711276https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/22711276","DOI":"10.1161\/CIRCULATIONAHA.112.103176"},{"key":"ref115","doi-asserted-by":"crossref","unstructured":"Zhao, Y. D., Courtman, D. W., Deng, Y., Kugathasan, L., Zhang, Q. and Stewart, D. J. (2005) Rescue of monocrotaline-induced pulmonary arterial hypertension using bone marrow-derived endothelial-like progenitor cells: efficacy of combined cell and eNOS gene therapy in established disease. Circulation Research 96, 442-450. 15692087https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/15692087","DOI":"10.1161\/01.RES.0000157672.70560.7b"},{"key":"ref116","doi-asserted-by":"publisher","unstructured":"Zhu, J. H., Wang, X. X., Zhang, F. R., Shang, Y. P., Tao, Q. M., Zhu, J. H. and Chen, J. Z. (2008) Safety and efficacy of autologous endothelial progenitor cells transplantation in children with idiopathic pulmonary arterial hypertension: open-label pilot study. Pediatr Transplant 12, 650-655.","DOI":"10.1111\/j.1399-3046.2007.00863.x18466198https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/18466198"}],"container-title":["Reviews in Cardiovascular Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.imrpress.com\/journal\/RCM\/21\/2\/10.31083\/j.rcm.2020.02.597","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,27]],"date-time":"2024-11-27T16:54:38Z","timestamp":1732726478000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.imrpress.com\/journal\/RCM\/21\/2\/10.31083\/j.rcm.2020.02.597"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6,30]]},"references-count":116,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2020]]}},"alternative-id":["2153-8174-21-2-2-163"],"URL":"https:\/\/doi.org\/10.31083\/j.rcm.2020.02.597","relation":{},"ISSN":["1530-6550","2153-8174"],"issn-type":[{"value":"1530-6550","type":"print"},{"value":"2153-8174","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,6,30]]},"article-number":"163"}}